Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Français FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Investors
  3. Regulated Information

Regulated Information

  • Regulated Information
  • Shareholders Meeting

Period

recent search

Reset

Showing: 1 – 05 of 167 Regulated Information

01 August 2023

01 August 2023

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 30 – 2023

27 July 2023

27 July 2023

Download Ipsen S.A. publishes its 2023 Half-Year Financial Report
Ipsen S.A. publishes its 2023 Half-Year Financial Report

25 July 2023

25 July 2023

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 29 – 2023

24 July 2023

24 July 2023

Download Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023
Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights – effective from December 19, 2023

18 July 2023

18 July 2023

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023
IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

1 … 20 21 22 23 24 25 26 … 34

IPN price

€166.40

 €-2.10 (-1.25%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?